Lupin receives EIR from US FDA for Aurangabad facility

The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated 

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Aurangabad manufacturing facility. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). 

“We are pleased to receive the EIR with VAI status from the US FDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide,” said Nilesh Gupta, MD, Lupin.